Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases by Rakislova, Natalia et al.
Rakislova et al. HPV-positive and –negative vulvar squamous cell carcinomas 1 
 
“Histological characteristics of HPV-associated and -independent 1 
squamous cell carcinomas of the vulva: a study of 1594 cases” 2 
Natalia Rakislova1, Omar Clavero2, Laia Alemany2,3, Adela Saco1, Beatriz 3 
Quirós2, Belen Lloveras4, Maria Alejo5, Michael Pawlita6, Wim Quint7, Marta del 4 
Pino8, Silvia de Sanjose2,3, Jaume Ordi1 on behalf of VVAP study group. 5 
1 Department of Pathology, ISGlobal, Hospital Clínic - Universitat de Barcelona, 6 
Barcelona, Spain 7 
2 Unit of Infections and Cancer, Cancer Epidemiology Research Program, 8 
Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Barcelona, 9 
Spain 10 
3 CIBER Epidemiologia y Salud Pública, Barcelona, Spain 11 
4 Department of Pathology, Hospital del Mar, Barcelona, Spain 12 
5 Department of Pathology, Hospital General d’Hospitalet, L’Hospitalet de 13 
Llobregat, Spain 14 
6 Division of Molecular Diagnostics of Oncogenic Infections, Research Program 15 
Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), 16 
Heidelberg, Germany 17 
7 DDL Diagnostic Laboratory, Rijswijk, The Netherlands 18 
8 Institute of Gynecology, Obstetrics and Neonatology, Hospital Clínic - Institut 19 
d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS). Faculty of 20 
Medicine-University of Barcelona, Spain 21 
Running title: 22 




Page 1 of 37 International Journal of Cancer




Corresponding author information:  29 
 30 
Jaume Ordi MD, PhD. 31 
 Pathology Department (CDB). Escala 3, Planta 5. Hospital Clinic. 08036 Barcelona. 32 
Spain.  33 
Tel. +34 93 227 54 50 / 5536 34 
Fax. +34 93 227 57 17 35 













Page 2 of 37International Journal of Cancer
Rakislova et al. HPV-positive and –negative vulvar squamous cell carcinomas 3 
 
ABSTRACT 49 
There are at least two different etio-pathogenic pathways for the development of 50 
vulvar squamous cell carcinoma (VSCC): one associated with infection by 51 
human papillomavirus (HPV) and another independent of HPV. We aimed to 52 
describe the histological characteristics of HPV-associated and HPV-53 
independent tumors and to determine the best strategy to identify HPV in 54 
VSCC.  A single paraffin block was available for review from a series of 1594 55 
VSCCs. In all cases HPV DNA detection was analyzed using the 56 
SPF10PCR/DEIA/LiPA25 system and p16 immunohistochemistry (IHC). A tumor 57 
was considered as unquestionably HPV-associated if both HPV DNA and p16 58 
IHC were positive. A tumor was considered indisputably HPV-independent if 59 
both HPV DNA and p16 IHC were negative. Two groups of tumors were 60 
classified as non-conclusive: 1) HPV DNA+/p16-; and 2) HPV DNA-/p16+. WHO 61 
typing and a thorough histological evaluation were conducted in all cases. 62 
441 tumors were HPV DNA+ with 367 cases (23.0%) being HPV DNA+/p16+. 63 
These HPV DNA+/p16+ tumors were more frequently basaloid or warty 64 
(49.8%), but 36.5% were of the keratinizing type. 1153 tumors were HPV DNA-, 65 
with 1060 cases (66.5%) being HPV DNA-/p16-. These HPV DNA-/p16- tumors 66 
were mostly keratinizing (81.2%) but were occasionally basaloid or warty 67 
(5.2%). The features of HPV DNA-/p16+ cases (n=93) were similar to those of 68 
the HPV-associated VSCC, and HPV DNA+/p16- (n=74) cases had a more 69 
diverse profile, although they were more similar to HPV-independent tumors. 70 
Several histological characteristics were more frequently associated with HPV-71 
related VSCC (koilocytotic-like change, necrosis, moderate to marked 72 
pleomorphism, invasive front in nests; p<0.001), however, none of these 73 
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characteristics allowed differentiation between HPV-associated and –74 
independent VSCC.  In conclusion, histological criteria do not allow 75 
differentiation between HPV-associated and –independent VSCC. p16 alone is 76 
a clinically easy strategy to determine HPV status in VSCC. 77 
 78 
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INTRODUCTION 79 
Vulvar squamous cell carcinoma (VSCC) accounts for less than 5% of the 80 
gynecological malignancies but represents more than 90% of the malignant 81 
tumors of the vulva 1. VSCCs can be subdivided into human papilloma virus 82 
(HPV)-associated and HPV-independent tumors, with HPV-associated tumors 83 
representing one-fifth to one-half of all VSCC 2–5 . Increasing evidence indicates 84 
that these two different types of VSCC not only have different epidemiological, 85 
clinical, pathological and molecular characteristics, but also a different clinical 86 
behavior.  These differences stress the need of considering HPV-associated 87 
and HPV-independent vulvar tumors as two separate entities 6–8. 88 
Most pathologists use clinico-pathological criteria to classify vulvar tumors 89 
as HPV-associated or –independent. The current WHO classification 9 90 
recognizes several histological variants of VSCC, including the basaloid, warty, 91 
keratinizing and non-keratinizing subtypes. HPV-associated tumors are 92 
considered to have a warty or basaloid histology 10–13, and affect younger 93 
women 14–19. Contrarily, HPV-independent lesions generally have a keratinizing 94 
morphology and occur in elderly women 14,20–24. However, a number of studies 95 
indicate that these pathological features have a limited usefulness to determine 96 
HPV status 14,20–22. Moreover, a comprehensive study analyzing histological 97 
characteristics of HPV-positive and –negative carcinomas has yet to be 98 
conducted.  99 
Recent studies have shown that HPV DNA alone may be insufficient to 100 
identify HPV-associated cancers outside the cervix 25–28. In recent years very 101 
sensitive and specific mRNA RT-PCR assays have been developed 28, but 102 
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these tests are extremely technically complex, and consequently are not 103 
adequate for pathology laboratories in routine daily practice.  104 
p16 immunohistochemistry (IHC) has shown to be a useful tool to classify 105 
VSCC into HPV-associated or –independent and is considered a good 106 
surrogate marker of HPV association in the vulva and in other anatomical sites 107 
in which HPV-associated and HPV-independent tumors are present 2,14,16,22,28–108 
32. However, many studies evaluating p16 IHC have included a limited number 109 
of cases and, consequently, the reliability of p16 positivity as a single marker of 110 
HPV–association is not known.  111 
Recently, the combination of two markers has been proposed as a reliable 112 
tool to provide robust results in terms of HPV status 2,28. In this strategy, tumors 113 
positive for HPV DNA and p16 would be indisputably HPV-associated, whereas 114 
tumors negative for the two biomarkers would be classified as unquestionably 115 
HPV-independent. However, it is not known whether the tumors with 116 
intermediate features (HPV DNA positive and p16 negative and HPV DNA 117 
negative and p16 positive) truly represent HPV-associated or –independent 118 
tumors.  119 
In this study, we analyzed a large series of 1594 tumors conducting a 120 
thorough histological analysis and detection of HPV using HPV DNA, p16 IHC 121 
and HPV mRNA. The study had three main goals: 1) to describe the histological 122 
characteristics of indisputably HPV-associated (HPV DNA+/p16+) and HPV-123 
independent tumors (HPV DNA-/p16-); 2) to determine the frequency and the 124 
features of the tumors with non-conclusive features (HPV DNA-/p16+ and HPV 125 
DNA+/p16-); and 3) to determine the best strategy to differentiate HPV-126 
associated and –independent tumors.  127 
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MATERIAL AND METHODS 128 
Study design and materials 129 
We reviewed all the invasive vulvar carcinomas previously analyzed in a 130 
retrospective cross-sectional survey coordinated by the Catalan Institute of 131 
Oncology (ICO, Barcelona-Spain) in collaboration with DDL Diagnostic 132 
Laboratory (Rijswijk, The Netherlands) 2,33. In the present analysis we included 133 
all the cases fulfilling the following inclusion criteria: 1) invasive squamous 134 
carcinoma identified in the block; and 2) adequate material for histological 135 
analysis, HPV detection and typing and p16 immunohistochemical stain. The 136 
case recruitment protocols have been reported previously. Of the 1709 invasive 137 
vulvar tumors included in the study, 47 were excluded because of non-138 
squamous histological types (i.e. basocellular or adenocarcinomas), and 68 139 
were excluded because no material was available for p16 staining. Thus, the 140 
study included1594 formalin-fixed paraffin-embedded (FFPE) vulva specimens 141 
collected from pathology archives from 38 countries from all continents (Mali, 142 
Mozambique,Nigeria, and Senegal in Africa; Argentina,Brazil, Chile, Colombia, 143 
Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay, the United States 144 
and Venezuela in the Americas; Bangladesh, India, Israel, South Korea, Kuwait, 145 
Lebanon, Philippines, Taiwan and Turkey in Asia; Austria, Belarus, Bosnia-146 
Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, 147 
Portugal, Spain and the United Kingdom in Europe; and Australia and New 148 
Zealand in Oceania). Five hundred seventy-five cases (36.1%) were small 149 
biopsies from vulvar tumors and 1019 (63.9%) cases came from large surgical 150 
excisions or vulvectomy specimens. The study was approved by local and ICO 151 
ethics committees. 152 
Page 7 of 37 International Journal of Cancer
Rakislova et al. HPV-positive and –negative vulvar squamous cell carcinomas 8 
 
Histological evaluation  153 
A single FFPE histological block was available from each case for review. 154 
Pathology evaluation was blind to HPV results and included a histological 155 
subtyping following the WHO 2014 classification 9. Basaloid tumors are 156 
characterized for being composed of small undifferentiated cells with little 157 
keratinization and koilocytosis. Warty subtype is defined by its condylomatous 158 
features, pleomorphism, striking koilocythic atypia and frequent keratinization. 159 
Non-keratinizing carcinoma is composed of sheets or nests of polygonal 160 
squamous cells and absence of keratin pearls. The keratinizing type is 161 
characterized by differentiated cells with keratin pearls and absence of 162 
koilocytosis. When mixed features were identified, the tumor was classified 163 
according to the main component, but other secondary components were also 164 
recorded.  165 
Additionally, the following histological characteristics were reported in all 166 
tumors: growth pattern (exophytic or endophytic), percentage of tumor nests 167 
showing keratin pearls, percentage of cells showing koilocytotic-like change, 168 
individual keratinization, and differentiated features (large, eosinophilic 169 
cytoplasm), percentage of tumor showing necrosis, extent of the inflammatory 170 
infiltrate adjacent to the tumor, and severity of the pleomorphism (these latter 171 
characteristics were semi-quantitatively evaluated as absent, mild, moderate or 172 
severe). The invasive front of the tumors was classified as having a nested 173 
(large or small nests) and diffuse pattern. Nested invasion consisted of either 174 
large geographic nests with frequent central comedo-type necrosis or small 175 
nests with frequent central keratin pearls 34. A diffuse (or infiltrative) front was 176 
defined by irregular cords or single atypical cells in a so-called spray pattern, 177 
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often with surrounding desmoplastic stroma. Pattern evaluations were 178 
performed at low-power (x4 to x10) magnification. Figure 1 shows the main 179 
histological features evaluated in all the tumors.  180 
Immunohistochemical staining for p16 and p53  181 
All tumors were stained with p16 monoclonal antibody using the CINtec 182 
Histology Kit (clone E6H4; Roche-Mtm-Laboratories, Heidelberg, Germany) 35. 183 
Only cases showing positivity in > 25% of tumor cells with strong and diffuse 184 
block staining of the basal layer were considered as positive (p16INK4a 185 
upregulation) 28,36. 186 
p53 immunohistochemistry was performed in the first 192 cases of the 187 
whole series of 1594 tumors. p53 was detected with the monoclonal anti-body 188 
DO-7 (Dako, Carpinteria, CA, USA). p53 was considered positive when more 189 
than 25% of the neoplastic cells showed nuclear staining. 190 
Tissue preparation, nucleic-acid isolation and HPV DNA detection  191 
DNA extraction was performed on whole sections of the formalin-fixed 192 
paraffin-embedded (FFPE) tissue from the surgical specimen or from pre-193 
treatment biopsy. The samples were serially sectioned on a microtome. The first 194 
and last sections (3 µm) were stained with H&E for histological confirmation of 195 
the diagnosis. In-between sections were collected in RNAase-free reaction 196 
tubes for DNA isolation (sandwich cutting technique). Sectioning and sample 197 
preparation were carried out with the highest measures to avoid cross-198 
contamination. Paraffin blocks lacking tissue were cut in-between the patient 199 
samples as controls to ensure the lack of contamination. Processing and 200 
pathology diagnosis were done by the reference laboratory. 201 
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DNA extraction and HPV DNA detection has been previously described 37. 202 
Briefly, HPV DNA detection was done using SPF10 PCR, DEIA and the LiPA25 203 
system (version 1, Laboratory Biomedical Products, Rijswijk, The Netherlands).  204 
HPV mRNA detection 205 
The mRNA extraction and mRNA detection from tissue ribbons were 206 
performed as previously described 28. For each case, HPV type-specific E6*I 207 
mRNA RT-PCR assays were performed for the HPV type(s) previously 208 
determined by genotyping and for a cellular ubiquitin C gene as a control for 209 
tissue quality. HPV E6*I mRNA assays were developed for the following HPV 210 
types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, 211 
and 82.  A second assay was performed to assess the presence of HPV16 E6*I 212 
mRNA in all cases, irrespective of the HPV DNA result. Cases with HPV mRNA 213 
positive (HPV mRNA+) and/or ubiquitin C mRNA+ signal were considered “RNA 214 
valid”. All “RNA invalid” samples [i.e. cases that were HPV mRNA negative 215 
(HPV mRNA-) and ubiquitin C mRNA-] were analyzed a second time, and 216 
according to the signals obtained, they were classified as “RNA valid” or “RNA 217 
invalid”.  218 
HPV E6*I mRNA was analyzed in all the HPV DNA positive cases and in a 219 
subset of 18 randomly selected HPV DNA cases as a negative control. A total of 220 
18 HPV DNA- cases were tested (10 HPV DNA-/p16- and 8 HPV DNA-/p16+ 221 
cases).  222 
 223 
Classification of tumors as HPV-associated and HPV-independent. Tumors with 224 
non-conclusive features 225 
Page 10 of 37International Journal of Cancer
Rakislova et al. HPV-positive and –negative vulvar squamous cell carcinomas 11 
 
A tumor was considered as unquestionably HPV-associated if both HPV 226 
DNA and p16 IHC were positive. A tumor was considered indisputably HPV-227 
independent if both HPV DNA detection and p16IHC were negative. These 228 
cases were considered the gold standard for HPV-positivity and –negativity, 229 
respectively. Two groups of tumors were classified as non-conclusive for HPV 230 
association: 1) tumors testing negative for HPV DNA but with positive staining 231 
for p16 (HPV DNA-/p16+); and 2) tumors testing positive for HPV DNA, but with 232 
negative result for p16 (HPV DNA+/p16-). 233 
Statistical analysis 234 
The results were reported as means, absolute frequencies and 235 
percentages. Chi-square analysis or Fisher’s exact test were used for 236 
comparisons between nominal variables. Data were analyzed with the program 237 
SPSS (version 15.0; SPSS, Inc, Chicago, IL). All statistical tests were two-238 
sided, and a p value of .05 or less was considered statistically significant. 239 
RESULTS 240 
HPV DNA, p16, p53, and histological typing: HPV-associated, HPV-independent 241 
tumors and tumors with non-conclusive features 242 
Four hundred forty-one tumors (27.7%) were positive for HPV DNA, and 243 
1153 (72.3%) were negative. Table 1 shows the WHO classification of the HPV-244 
positive and -negative tumors. HPV-positive tumors were more frequently 245 
basaloid or warty (198 out of 441; 44.9%), while 42.0% were of the keratinizing 246 
type. HPV-negative tumors were more frequently keratinizing (905 out of 1153; 247 
78.5%), but were occasionally of basaloid or warty type (88 out of 1153; 7.6%). 248 
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Mixed features, with presence of warty or basaloid along with keratinizing 249 
areas were identified in 96/1594 tumors (6.0%). Mixed features were observed 250 
in 30/441 (6.8%) HPV-positive tumors (6/160 [3.1%] basaloid, 4/38 [10.5%] 251 
warty, 5/56 [8.9%] non-keratinizing, 15/185 [8.1%] keratinizing) and in 66/1153 252 
(5.7%) HPV-negative tumors (7/55 [12.7%] basaloid, 9/33 [27.3%] warty, 12/141 253 
[8.5%] non-keratinizing, 38/905 [4.2%] keratinizing). 254 
Three hundred sixty-seven out of 441 HPV DNA positive tumors (83.2%) 255 
were positive for p16 IHC; on the other hand, one thousand sixty out of 1153 256 
HPV DNA negative tumors (91.9%) were negative for p16 IHC. The percentage 257 
of tumors of basaloid or warty type slightly increased in HPV-associated tumors 258 
(49.8%), whereas the percentage of histologically keratinizing tumors slightly 259 
increased in HPV-independent tumors (81.2%). Figure 2 shows an example of 260 
unquestionably HPV-associated VSCC with keratinizing histology (HPV 261 
DNA+/p16+), and two indisputably HPV-independent VSCC (HPV DNA-/p16-) 262 
with basaloid and warty characteristics. 263 
One hundred sixty-seven tumors (10.5%) showed a non-conclusive profile. 264 
Ninety-three tumors were HPV DNA-/p16+; and 74 tumors were HPV 265 
DNA+/p16-. Table 2 shows the WHO classification and age distribution of the 266 
indisputably HPV-associated tumors (HPV DNA+/p16+), the unquestionably 267 
HPV-independent tumors (HPV DNA-/p16- tumors) and the tumors with non-268 
conclusive profiles. The tumors with a HPV DNA-/p16+ profile were similar to 269 
the indisputably HPV-associated tumors in terms of WHO typing (p>0.05). The 270 
HPV DNA+/p16- tumors had indeterminate features, although they were more 271 
similar to the unquestionably HPV-independent tumors (slightly higher 272 
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proportion of warty-basaloid tumors in the HPV DNA+/p16- group compared 273 
with HPV DNA-/p16- group; p<0.001).  274 
There were marked differences between these two groups in terms of age   275 
(61.7 ± 16.7 in the indisputably HPV-associated tumors vs. 71.7 ± 13.4, in the 276 
unquestionably HPV-independent tumors; p<0.001). Interestingly, the mean age 277 
of the patients with tumors with a HPV DNA-/p16+ profile was similar to that of 278 
the women with indisputably HPV-associated tumors (p>0.05). Contrarily, the 279 
HPV DNA+/p16- cases were similar in age distribution to the HPV-independent 280 
tumors. 281 
From the subset of 192 tumors stained for p53, a positive result was 282 
observed in 2 out of 40 (5%) unquestionably HPV-associated tumors (HPV 283 
DNA+/p16+ profile) and in 88 out of the 140 (62.9%) unquestionably HPV-284 
independent tumors (HPV DNA-/p16- profile). In the group of HPV DNA-/p16+ 285 
tumors, p53 was negative in all six tumors tested (0/6; 0%), whereas in the 286 
group of HPV DNA+/p16- tumors, 4/6 (66.7%) were positive for p53.  287 
Histological characteristics of unquestionable HPV-associated and –288 
independent tumors  289 
Table 3 shows the histological characteristics of the indisputably HPV-290 
associated tumors and the unquestionably HPV-independent tumors, as well as 291 
the characteristics of the HPV DNA positive and negative tumors without p16 292 
IHC. Several histological characteristics were more frequently associated with 293 
HPV-associated tumors (koilocytotic-like change, necrosis, moderate to marked 294 
pleomorphism, invasive front in nests; p<0.001), whereas individual 295 
keratinization, keratin pearls, highly differentiated cells and a diffuse invasive 296 
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front were more frequently associated with HPV-independent VSCC (p<0.001). 297 
However, none of the histological features allowed reliable differentiation 298 
between the two types of VSCC as all of the characteristics were present in a 299 
proportion of both types of tumors. 300 
HPV typing and histological classification 301 
Table 4 shows the results of the HPV typing and the histological 302 
classification of the tumors according to the typing in the 441 cases positive for 303 
HPV DNA and in the group of 367 unquestionable HPV-associated tumors. 304 
HPV16 was, by far, the type most frequently identified.  305 
p16 IHC was positive in over 90% of cases positive for HPV16 and 45, in 306 
over 80% of the cases positive for HPV18 and 33, in over 70% of multiple HPV 307 
infections and infections by other high-risk HPV, in 30% of infections by 308 
undetermined HPV types and was negative in tumors caused by low-risk HPV. 309 
The percentage of tumors with basaloid or warty histology ranged from 70% in 310 
HPV33 positive tumors to less than 40% in HPV 18 or HPV45 positive tumors.  311 
HPV mRNA detection 312 
Adequate material for mRNA detection was available in 402 out of the 441 313 
(91.1%) HPV DNA positive tumors. HPV mRNA was identified in 350/402 314 
tumors (87.1%). Five cases were considered as “RNA invalid”. Type-specific 315 
HPV mRNA was not analyzed in the tumors caused by undetermined (n=19),  316 
low-risk HPV (n=12), and in three tumors associated with high-risk types 30, 69, 317 
and 102, as the probes were not designed against these viruses. HPV mRNA 318 
was positive in 334/352 (94.9%) of the unquestionably HPV-associated tumors 319 
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(HPV DNA+/p16+) and in only 16/50 (32%) of the HPV DNA+/p16- tumors 320 
(p<0.001). 321 
In the subset of 18 HPV DNA negative tumors tested for mRNA, eight 322 
tumors were HPV DNA-/p16+ and 10 HPV DNA-/p16-. Two out of eight (25%) 323 
HPV DNA-/p16+ tumors were positive for HPV mRNA, whereas none of the 10 324 
unquestionably HPV-independent tumors (HPV DNA-/p16-) were positive for 325 
HPV mRNA.  326 
DISCUSSION 327 
The present study, which includes a large number of VSCCs, confirms 328 
previous results obtained by our group 14,16, showing that there is significant 329 
overlap between the histological types of VSCC and the association with HPV. 330 
Indeed, 36.5% of the unquestionable HPV-associated VSCCs were of the 331 
conventional keratinizing type, the histological type considered as characteristic 332 
of the HPV-independent pathway of VSCC 3,5,14,16,38–40 On the other hand, a 333 
small, albeit significant, number of indisputably HPV-independent VSCCs 334 
showed basaloid or warty features (5.2%), the histological types usually 335 
considered as associated with HPV-driven VSCCs 3,5,14,16,38,41,42. This high 336 
prevalence of HPV infection among keratinizing VSCCs has also been 337 
observed by other authors, who have found percentages similar to or higher 338 
than those observed in our study 2,14,20,43–45. Thus, the present results confirm 339 
the limited reliability of the current WHO classification of VSCCs in terms of 340 
HPV attribution 5,14,41.  341 
The poor correlation observed between histological typing and HPV 342 
infection may be related, in part, by a certain degree of subjectivity in 343 
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subclassifying the tumors observed in our study as previously referred by some 344 
authors 14,41. These difficulties are particularly challenging in the diagnosis of 345 
non-keratinizing carcinoma and to a lesser extent, warty carcinomas 14. In 346 
addition, the presence of keratinization in basaloid carcinomas can hinder the 347 
differential diagnosis with poorly differentiated keratinizing squamous cell 348 
carcinomas. Moreover, mixed basaloid-keratinizing squamous carcinomas 349 
posing serious diagnostic problems have been described 17. 350 
The marked overlap observed in all the histological features evaluated in 351 
our study clearly highlights the absence of specific criteria that allow classifying 352 
a tumor as HPV-associated or –independent. Indeed, although many of the 353 
histological findings evaluated in our study showed significant differences 354 
between the two groups, all the characteristics were found in a large proportion 355 
of HPV-associated and –independent tumors. A particularly unspecific feature is 356 
the presence of koilocytotic-like changes, which were observed in 11.6% of the 357 
HPV-independent VSCCs. Moreover, a marked interobserver variability in the 358 
separation between pseudokoilocytotic and true koilocytotic changes has been 359 
reported 14,46. These findings further stress the poor validity of morphology 360 
alone to distinguish the two etio-pathogenic types of VSCC 5,14,20–22,25,41,47. 361 
Our study shows that 10.5% of the tumors had non-conclusive features in 362 
terms of HPV attribution assessed by HPV DNA and p16. The most frequent 363 
group (HPV DNA-/p16+) was comparable to the unquestionably HPV-364 
associated group in terms of age and histological typing. These findings indicate 365 
that these cases may represent false negative results of HPV DNA detection. In 366 
these cases the poor tissue quality could have contributed to the false negative 367 
HPV DNA result 2. In contrast, the other non-conclusive group (HPV DNA+/p16-368 
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) is more heterogeneous. It includes the unusual VSCCs (12 cases) harboring 369 
only a low-risk HPV, which have been shown to be negative for p16 IHC 48. 370 
Some of the cases represented p16 negativity in truly HPV-positive tumors, as 371 
shown by the identification of 16 tumors positive not only for HPV DNA but also 372 
for HPV mRNA. However, it is likely that some of these cases are false positive 373 
HPV DNA cases. This group was more similar to the indisputably HPV-374 
independent group in terms of histological characteristics and age range. 375 
Moreover, the infrequent presence of mRNA in these tumors (32.0% vs. 94.9% 376 
in the HPV DNA+/p16+ group) after excluding all cases not tested for mRNA 377 
HPV, as the test was not designed for low-risk and undetermined HPV types, is 378 
also in keeping with this hypothesis. As the whole FFPE block was tested for 379 
HPV detection without performing tumor microdissection, we cannot exclude the 380 
possibility of contamination from the adjacent embedded tissue not related to 381 
the tumor. Thus, our results suggest that HPV DNA detection alone could 382 
misclassify up to 10% of cases, whereas despite not being perfect, p16 383 
immunohistochemistry could be a more reliable tool, offering even better 384 
sensitivity and specificity. 385 
p53 IHC was positive in only 5% of the unquestionably HPV-associated 386 
tumors and in 66.7% of the unquestionably HPV-independent tumors. These 387 
results are in keeping with previous reports showing that p53 abnormalities are 388 
infrequent  in HPV-associated tumors and present in about two thirds of HPV-389 
independent  tumors 14,49. Interestingly, the percentage of p53 positivity in HPV 390 
DNA-/p16+ tumors was comparable to the unquestionably HPV-associated 391 
neoplasms whereas HPV DNA+/p16- tumors were more similar to the 392 
indisputably HPV-independent carcinomas. These results add further evidence 393 
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indicating that DNA-/p16+ tumors probably represent false negative results of 394 
HPV DNA detection, whereas many of the HPV DNA+/p16- tumors are false 395 
positive HPV DNA cases. 396 
In situ hybridization assays that can detect HPV E6/E7 mRNA in FFPE 397 
tissue and allow visualization of the transcripts within tumor cells have recently 398 
become available. Although the value of these assays needs to be confirmed, 399 
they might help in the identification of HR-HPV-associated neoplasia in the 400 
vulva, the anus and the head and neck region 50. 401 
The main strength of the present study is that it includes a very high 402 
number of VSCC, and in all the cases, a detailed histological review and 403 
thorough molecular analysis including HPV DNA, mRNA and p16 were 404 
performed. The correlation of all the data allowed the study to obtain more 405 
accurate evidence of HPV involvement in the large series of tumors 28. 406 
The study also has some limitations. Only one FFPE block per case was 407 
available for review. This may, to some extent, have influenced the histological 408 
type distribution and, particularly, may have resulted in a relatively high 409 
percentage of non-keratinizing tumors, as keratin pearl formation may have 410 
been focal or absent in the area sampled. Additionally, although HPV DNA 411 
detection in this study has fulfilled strict quality controls, the different tissue 412 
processing techniques performed in a large variety of contributing laboratories 413 
could have had an impact on our results. However, the high number of cases 414 
analyzed and the strict quality controls used for p16 staining and HPV DNA and 415 
RNA detection have probably minimized this effect. 416 
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         Finally, the complete absence of clinical and follow-up data prevents 417 
obtaining any conclusions on the prognostic implications of HPV status. 418 
Although there are some discordant results on the prognostic significance of 419 
HPV in VSCC 8,20, recent evidence indicates a strong association between 420 
positive p16 IHC and lower FIGO stage and negative lymph node metastasis 7, 421 
and that the presence of HPV DNA or positive p16 IHC is an independent 422 
prognostic factor 6. 423 
In conclusion, the present study performed in a large number of cases of 424 
vulvar carcinomas confirms that histological criteria do not allow differentiation 425 
between HPV-associated and –independent VSCC. Although not perfect, p16 is 426 
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LEGEND OF FIGURES 663 
FIGURE 1. Histological characteristics evaluated in the study: A) koilocytotic-like 664 
change; B) necrosis; C) moderate to marked pleomorphism; D) individual 665 
keratinization, keratin pearls, and highly differentiated cells; E) invasive front in 666 
nests; F) diffuse invasive front. Hematoxylin and eosin staining. 667 
FIGURE 2.  A) Keratinizing VSCC unquestionably HPV-associated tumor (HPV 668 
DNA+/p16+); B) indisputably HPV-independent VSCC (HPV DNA-/p16-) of 669 
basaloid type; C) indisputably HPV-independent VSCC (HPV DNA-/p16-) of 670 
warty type. Hematoxylin and eosin staining (A, B, C) and p16 671 
immunohistochemistry (A’, B’, C’). 672 
 673 
 674 
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Table 1. WHO classification of the human papillomavirus (HPV)-associated and 














The statistical significant p-values are highlighted in bold (corrected p-value for 
multiple comparison; 0.05/6=0.008). 
 
  HPV DNA+                  
(n=441) 
HPV DNA-                  
(n=1153) 
 
  n (%) n (%) p-value 
Keratinizing 185 (42.0) 905 (78.5) 0.000 
Non-keratinizing 56 (12.7) 141 (12.2) 0.786 
Basaloid 160 (36.3) 55 (4.8) 0.000 
Warty 38 (8.6) 33 (2.9) 0.000 
Verrucous 1 (0.2) 15 (1.3) 0.087 
Spindle cell 1 (0.2) 4 (0.3) 0.999 
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Table 2. WHO classification of the human papillomavirus (HPV)-associated and 
–independent tumors, defined by HPV DNA and p16 detection.  
 
1) p-value: comparison of the gold standard for positivity and negativity (HPV 
DNA+ andp16+ vs HPV DNA- and p16-) 
SD: Standard deviation. 
The statistical significant p-values are highlighted in bold (corrected p-value for 
multiple comparisons; 0.05/6=0.008). 
 
 Gold standard groups Non-conclusive groups  













  n (%) n (%) n (%) n (%) p-value1 
Keratinizing 134 (36.5) 861 (81.2) 44 (47.3) 51 (68.9) 0.000 
Non-keratinizing 49 (13.4) 124 (11.7) 17 (18.3) 7 (9.5) 0.403 
Basaloid 152 (41.4) 27 (2.5) 28 (30.1) 8 (10.8) 0.000 
Warty 31 (8.4) 29 (2.7) 4 (4.3) 7 (9.5) 0.000 
Verrucous 0 (0.0) 15 (1.4) 0 (0.0) 1 (1.4) 0.016 
Spindle cell 1 (0.3) 4 (0.4) 0 (0.0) 0 (0.0) 1.000 
Age range [min-max] [22-97] [18-104] [24-94] [33-92]  
Mean age (SD) 61.7 (16.7) 71.7 (13.4) 64.8 (15.0) 68.8 (14.4) 0.000 
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Table 3. Histological characteristics of the human papillomavirus (HPV)-associated and –independent tumors. 
 
 HPV DNA+                  
(n=441) 
HPV DNA-                  
(n=1153) 
HPV DNA+ and 
p16+ (n=367) 
HPV DNA- and  
p16- (n=1060) 
 
  n (%) n (%) n (%) n (%) p-value1 
Pattern of growth 
 
 
   
Exophytic 106 (24.0) 221 (19.2) 83 (22.6) 206 (19.4) 0.191 
Endophytic 335 (76.0) 932 (80.8) 284 (77.4) 854 (80.6) 0.191 
Koilocytotic-like change 154 (34.9) 145 (12.6) 121 (33.0) 123 (11.6) 0.000 
Inflammatory infiltrate 283 (64.2) 720 (62.4) 234 (63.8) 658 (62.1) 0.566 
Individual keratinization 223 (50.6) 832 (72.2) 170 (46.3) 780 (73.6) 0.000 
Keratin pearls 307 (69.6) 1009 (87.5) 246 (67.0) 946 (89.2) 0.000 
Differentiated cells ≥10% 339 (76.9) 1071 (92.9) 271 (73.8) 999 (94.2) 0.000 
Necrosis 279 (63.3) 610 (52.9) 231 (62.9) 547 (51.6) 0.000 





Large or small nests 260 (59.0) 484 (42.0) 224 (61.0) 438 (41.3) 0.000 
Diffuse 181 (41.0) 669 (58.0) 143 (39.0) 622 (58.7) 0.000 
1) p-value: comparison of gold standards for positivity and negativity, that is HPV DNA+ AND p16+ vs HPV DNA- AND p16- 
The statistical significant p-values are highlighted in bold (corrected p-value for multiple comparisons; 0.05/11=0.005). 
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Table 4. Histological World Health Organization (WHO) classification according to human papillomavuirus (HPV) genotyping. 
 HPV DNA positive (n=441)  HPV DNA positive and p16 positive (n=367) 
  WHO histological classification   WHO histological classification 








HPV infection n n (%) n (%)  n n (%) n (%) 
Single HPV16 296 139 (47.0) 157 (53.0)  269 133 (49.4) 136 (50.6) 
Single HPV33 23 15 (65.2) 8 (34.8)  20 14 (70.0) 6 (30.0) 
Single HPV18 16 5 (31.3) 11 (68.7)  13 5 (38.5) 8 (61.5) 
Single HPV45 13 5 (38.5) 8 (61.5)  13 5 (38.5) 8 (61.5) 
Single high risk infections by 
HPV other than 16, 18, 33 or 45a 
38 17(44.7) 21(55.3)  28 13(46.4) 15(53.6) 
Multiple infections including at 
least one high risk HPV typeb 
24 11(45.8) 13 (54.2)  18 10 (55.5) 8(44.4) 
Low-risk HPV infectionsc 12 2(16.7) 10(83.3)  0 - - 
Undetermined 19 4 (21.1) 15 (78.9)  6 4 (66.7) 2 (33.3) 
a Includes infections by HPV 26 (1 case), 30 (1 case), 31 (4 cases), 35 (1 case), 39 (4 cases), 51 (2 cases), 52 (9 cases), 56 (6 cases), 58 (4 cases), 68 (2 
cases), 69 (1 case), 70 (1 case), 73 (1 case), and 102 (1 case) 
b Includes a) double infections by HPV6 and 16 (n=4); HPV16 and 18 (n=2); HPV16 and 31 (n=1); HPV16 and 33 (n=1); HPV16 and 51 (n=1); HPV18 and 
11 (n=1); HPV18 and 44 (n=2); HPV18 and 74 (n=1); HPV31 and 33 (n=1); HPV31 and 42 (n=1); HPV33 and 56 (n=1); HPV35 and 66 (n=1); HPV44 and 
45 (n=1); HPV44 and 58 (n=1); HPV44 and 66 (n=1); b) triple infections HPV31, 33 and 58 (n=1); HPV51, 68 and 73 (n=1); and c) quadruple infections 
HPV31, 33, 44 and 45 (n=1); and HPV51, 53, 54 and 58 (n=1) 
c Includes single infections by HPV 6 (n=2), 11 (n=1), 44 (n=3), 53 (n=1), 61 (n=2), 74 (n=2) and a double infection 42 and 7 (n=1). 
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FIGURE 1. Histological characteristics evaluated in the study: A) koilocytotic-like change; B) necrosis; C) 
moderate to marked pleomorphism; D) individual keratinization, keratin pearls, and highly differentiated 
cells; E) invasive front in nests; F) diffuse invasive front. Hematoxylin and eosin staining.  
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FIGURE 2.  A) Keratinizing VSCC unquestionably HPV-associated tumor (HPV DNA+/p16+); B) indisputably 
HPV-independent VSCC (HPV DNA-/p16-) of basaloid type; C) indisputably HPV-independent VSCC (HPV 
DNA-/p16-) of warty type. Hematoxylin and eosin staining (A, B, C) and p16 immunohistochemistry (A’, B’, 
C’).  
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